autologous and allogeneic tumor cell vaccine (University of Miami)

This investigational cancer immunotherapy, developed at the University of Miami, is a cell-based vaccine designed for the treatment of advanced or recurrent non-small cell lung cancer (NSCLC). It consists of a combination of irradiated autologous tumor cells and irradiated allogeneic tumor cells (specifically the AD100 adenocarcinoma line). The allogeneic component is genetically engineered to secrete gp96-Ig (endoplasmin) and express the costimulatory molecule B7-1 (CD80). The mechanism involves gp96-Ig acting as a chaperone for tumor antigens and an adjuvant that binds to the CD91 (LRP1) receptor on dendritic cells, while CD80 provides necessary costimulation by binding to CD28 on T cells. This dual stimulation is intended to enhance antigen cross-presentation and activate a robust cytotoxic T-lymphocyte (CTL) response against both patient-specific and shared tumor antigens, aiming to overcome tumor-mediated immune suppression.

Other names

gp96-Ig transfected allogeneic tumor cell vaccinegp-96-Ig transfected allogeneic tumor cell vaccinegp 96-Ig transfected allogeneic tumor cell vaccineB7-1/gp96-Ig tumor cell vaccineAD100-based vaccineAD-100-based vaccineAD 100-based vaccineautologous tumor cell vaccine + allogeneic tumor cell vaccine